Seres Therapeutics Receives Upgrade to Hold Rating

Seres Therapeutics (NASDAQ:MCRB) has been upgraded from a "sell" rating to a "hold" rating according to a report released by StockNews.com on Friday. This change in rating reflects a shift in analysts' perspectives regarding the company's stock performance.

Additionally, other financial institutions have recently shared their opinions on Seres Therapeutics. For instance, JPMorgan Chase & Co. downgraded the company from a "neutral" rating to an "underweight" rating in a report dated October 24th. On the other hand, Canaccord Genuity Group reaffirmed a "buy" rating for Seres Therapeutics and set a price target of $10.00 in their research published on November 14th. Similarly, Chardan Capital also holds a "buy" rating and has set a target price of $1.25 as of November 13th. Overall, one analyst rates the stock as a sell, two give it a hold rating, and two others have a buy rating. According to MarketBeat, Seres Therapeutics has an average rating of "hold" and a consensus price target of $5.08.

Recent Stock Performance

On Friday, Seres Therapeutics shares saw a minor decrease of $0.01, bringing the stock down to $0.83. A total of 491,114 shares were traded, which is less than the average trading volume of 1,759,622 shares. The company has a market capitalization of $142.17 million, with a price-to-earnings (PE) ratio of -3.62 and a beta of 2.11. The shares have a moving average of $0.85 over the last 50 days and $0.87 over the past 200 days. Over the past year, Seres Therapeutics has reached a low of $0.54 and a high of $1.53.

Activity of Institutional Investors

Recent activity among institutional investors and hedge funds shows that there have been several changes in holdings of Seres Therapeutics. Jane Street Group LLC increased its position in the company by 181.4% during the fourth quarter, acquiring an additional 37,866 shares, resulting in a total of 58,736 shares owned. Northern Trust Corp also raised its stake in the company by 20.4%, bringing its total holdings to 262,683 shares after purchasing 44,461 more shares. Furthermore, Geode Capital Management LLC grew its shareholding by 8.8%, while Avantax Advisory Services Inc. expanded its position by 170.9%, acquiring 28,500 additional shares. Charles Schwab Investment Management Inc. enhanced its stake by 15.6% with the purchase of 117,107 shares. Currently, approximately 59.34% of Seres Therapeutics' stock is owned by hedge funds and other institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc. specializes in microbiome therapeutics and is focused on developing innovative biological drugs aimed at modulating the colonic microbiome. The company’s goal is to treat diseases by restoring the microbiome to a healthier state.

Seres, Therapeutics, stocks